Big Money Sentiment decreased to 1.13 in 2018 Q4. It has change of 0.02, from 2018Q3’s 1.15. The ratio dropped due to Meridian Bioscience, Inc. positioning: 18 sold and 53 reduced. 34 funds amassed positions and 46 increased positions. Investors holded 37.34 million in 2018Q3 but now own 38.14 million shares or 2.14% more.
Prelude Capital Ltd Co holds 752 shs or 0% of its capital. 3,502 were accumulated by Zurcher Kantonalbank (Zurich Cantonalbank). Stone Ridge Asset Lc reported 39,147 shs. Robecosam Ag accumulated 25,400 shs. Connor Clark Lunn Invest Ltd reported 22,850 shs. Brown Limited Liability Co reported 0.76% of its capital in Meridian Bioscience, Inc. (NASDAQ:VIVO). Teachers Retirement Of The State Of Kentucky holds 0% or 16,229 shs. D E Shaw And Company holds 0.01% or 384,240 shs. Hsbc Holding Public Limited Company reported 54,069 shs. Arcadia Inv Mi holds 0.01% or 1,000 shs. Metropolitan Life Insur Company reported 0.01% of its capital in Meridian Bioscience, Inc. (NASDAQ:VIVO). Connors Investor invested 0.46% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Commonwealth Of Pennsylvania Public School Empls Retrmt has 0% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO). Hotchkis And Wiley Cap Mngmt Lc accumulated 162,873 shs. Fuller & Thaler Asset, a California-based fund reported 1,650 shs.

Meridian Bioscience, Inc. had 1 insider sale and 0 insider buys since November 12, 2018. This’s net activity of $681,229.

On April, 25 WallStreet awaited Meridian Bioscience, Inc. (NASDAQ:VIVO)’s earnings release, Zacks reports. This year’s EPS analyst estimate is awaited to be $0.21. That is 0.00 % compareed to $0.21 EPS for last year. If $0.21 is reported, VIVO’s profit will reach $8.92M for 20.96 P/E. Analysts at Wall Street see Meridian Bioscience, Inc.’s 5.00 % EPS growth compared to $0.20 EPS for last quarter. Ticker’s shares touched $17.61 during the last trading session after 1.27% change.Meridian Bioscience, Inc. has volume of 147,990 shares. Since March 30, 2018 VIVO has risen 23.48% and is uptrending. VIVO outperformed the S&P 500 by 19.11%.

Meridian Bioscience, Inc., a life science company, develops, makes, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide.The firm is valued at $748.24 million. The firm operates through Diagnostics and Life Science divisions.29.35 is the P/E ratio. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays that can be used in point-of-care settings under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the Premier brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand.

For more Meridian Bioscience, Inc. (NASDAQ:VIVO) news brought out recently go to: Seekingalpha.com, Nasdaq.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Precision BioSciences Files IPO Plan – Seeking Alpha” brought out on March 05, 2019, “GeoVax Provides Product Development and Corporate Update – Nasdaq” on March 11, 2019, “Homology Medicines Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Recent Accomplishments – Nasdaq” with a publish date: March 12, 2019, “Organogenesis Holdings Inc. Announces ReNu® Clinical Trial Results at AAOS 2019 Annual Meeting – Nasdaq” and the last “Orchard Therapeutics Presents New Registrational Data Demonstrating Sustained Clinical Benefit of OTL-200 for the Treatment of MLD – Nasdaq” with publication date: March 27, 2019.